ObjectiveTo explore whether fluoroethylnormemantine （FENM）， an NMDA receptor antagonist， could improve compulsive-like behaviors and to investigate its underlying mechanisms in the RU24969-induced obsessive-compulsive disorder （OCD） mouse model. MethodsThirty-two mice were randomly assigned to four groups： Saline （n=8）， RU24969 （n=8）， RU+FENM （n=8）， and FENM （n=8）. Mice received FENM or an equivalent volume of saline for pre-treatment， followed by RU24969 or saline for model induction 30 minutes later. Behavioral tests were performed 1 hour after modeling， and serum samples were collected to measure the level of brain-derived neurotrophic factor （BDNF）. Evans Blue dye was intravenously injected to assess dye content in brain tissue， thereby evaluating potential blood-brain barrier damage. ResultsFENM treatment significantly improved repetitive stereotyped circling behavior （F=39.850， P＜0.001） and alleviated persistent motor activity （F=50.200， P＜0.001） in RU24969 model mice. Additionally， FENM treatment significantly increased serum BDNF level in RU24969-induced OCD mice （F=18.930， P＜0.001）. ConclusionsFENM ， an NMDA receptor antagonist， may alleviate compulsive behaviors in OCD mice by modulating BDNF levels ， thereby exerting anti-compulsive effects. Neither the RU24969 model nor FENM treatment significantly affectes blood-brain barrier integrity.

OBJECTIVE: To investigate the clinical characteristics and related risk factors of Clostridium difficile infection (CDI) in intensive care unit (ICU). METHODS: A retrospective study was conducted. Patients with diarrhea admitted to the ICU of the General Hospital of Ningxia Medical University from May 1 to August 30, 2023 were selected. Patients were divided into CDI group and non-CDI group based on the presence or absence of CDI. Clinical data from two groups of patients meeting the criteria were collected and compared, including gender, age, acute physiology and chronic health evaluation II (APACHE II), length of hospital stay, serum lactic acid, parenteral nutrition time, white blood cell count (WBC), procalcitonin (PCT), C-reactive protein (CRP), coagulation indicators, albumin, antibiotic exposure, etc. Multivariate Logistic regression analysis was performed to analyze the risk factors for CDI in ICU diarrhea patients. Receiver operator characteristic curve (ROC curve) was drawn to analyze the predictive value of each index for CDI in diarrhea patients. RESULTS: A total of 24 patients with diarrhea were enrolled, including 9 patients in the CDI group and 15 patients in the non-CDI group. The time of parenteral nutrition in the CDI group was significantly longer than that in the non-CDI group [days: 18.0 (13.5, 19.5) vs. 10.0 (4.0, 18.0)], the serum lactic acid level [mmol/L: 4.40 (3.00, 15.25) vs. 2.50 (1.90, 3.20)] and the ratio of serum lactic acid > 3.9 mmol/L [66.67% (6/9) vs. 6.67% (1/15)] were significantly higher than those in the non-CDI group, with statistical significance (all P < 0.05). Multivariate binary Logistic regression analysis showed that the serum lactic acid level of the patients was an independent risk factor for CDI [odds ratio (OR) = 3.193, 95% confidence interval (95%CI) was 1.011-10.080, P = 0.048]. ROC curve showed that serum lactic acid level had a high predictive value for CDI in ICU patients with diarrhea, and the area under the curve (AUC) was 0.815, respectively. When the cut-off value of serum lactic acid was 3.9 mmol/L, the sensitivity was 66.7% and the specificity was 93.3%. CONCLUSION Patients with diarrhea who have higher serum lactate levels (> 3.9 mmol/L) on admission are at increased risk of developing CDI.
Humans ; Retrospective Studies ; Risk Factors ; Intensive Care Units ; Clostridium Infections ; Clostridioides difficile ; Male ; Female ; Middle Aged ; Aged ; Diarrhea/microbiology* ; Logistic Models ; ROC Curve ; Adult

BACKGROUND:Crosslinked sodium hyaluronate gel has good mechanical property,biocompatibility,and biodegradability,and can be used as an isolated protective material in tumor radiation therapy to protect endangered organs from damage caused by excess radiation dose. OBJECTIVE:To investigate the safety and efficacy of crosslinked sodium hyaluronate gel in reducing the dose of radiation to dangerous organs during brachytherapy. METHODS:A total of 16 specific pathogen-free Kunming mice of the same age and similar body weight were selected as experimental subjects and divided into experimental group and control group by the random number table method,with 8 mice in each group.125I seeds were implanted subcutaneously in the back of mice in the experimental group,and then crosslinked sodium hyaluronate gel was injected around the radioactive particles.Only 125I seeds were implanted subcutaneously in the back of mice in the control group.After injection,the distance between the radioactive particles and the epidermis was measured by spiral CT scan,and the surface radiation dose was measured by radiation dosimeter.Within 10 weeks after injection,the growth state,survival rate,skin radiation damage,and gel retention of mice were observed. RESULTS AND CONCLUSION:(1)Spiral CT scan showed that the implanted gel was relatively concentrated and created an effective distance between the radioactive seeds and the epidermis.The body surface radiation dose of the experimental group was significantly lower than that of the control group(P<0.01).(2)During the experimental observation period,mice in both groups survived;mice in the control group showed obvious irritability and other unstable behavior in the late experimental period,and some mice in the experimental group showed similar behavior.The daily food intake of mice in the two groups had no significant change,and the body mass showed the same increasing trend.After implantation of radioactive seeds,the two groups of mice showed different degrees of radioactive skin injury.From day 23 after injection to the end of the experiment,the skin radiation injury score of the experimental group was lower than that of the control group(P<0.01).At week 10 after implantation,6 mice in the experimental group had no obvious gel residue under their skin,and 2 mice had a very small amount of scattered gel-like samples under their skin.(3)Therefore,the crosslinked sodium hyaluronate injection technique can increase the space between the radioactive target area of 125I seeds and the organ at risk outside the target through physical space occupying,which can effectively reduce the dose of the organ at risk,and play a role in the isolation and protection of the organ at risk.

Objective:To summarize and analyze the clinical characteristics, drug resistance and treatment of 36 neonates with Enterobacter sepsis in the Children′s Hospital of Soochow University in the past 3 years, so as to provide reference for clinical treatment.Methods:A retrospective analysis was conducted on neonates hospitalized in the Department of Neonatology of the Children′s Hospital of Soochow University from January 2021 to March 2024 who were diagnosed with Enterobacter sepsis. The birth status, clinical manifestations, blood culture drug sensitivity, treatment status and disease outcome of the neonates were analyzed.Results:A total of 36 neonates with Enterobacter sepsis were collected. Premature infants accounted for 38.9%(14/36), and late-onset cases accounted for 66.7%(24/36). The incidence of complications was high. The main complications were central nervous system infection (15/36, 41.7%), urinary system infection (13/36, 36.1%) and neonatal necrotizing enterocolitis (7/36, 19.4%). The main pathogenic bacteria were Escherichia coli (19 cases) and Klebsiella (11 cases). Among the 19 escherichia coli strains, 7 were extended-spectrum β-lactamase (ESBL)-producing strains and 1 was carbapenem-resistant enterobacteriaceae (CRE) strain. Among the 11 Klebsiella strains, 9 were ESBL-producing strains and 6 were CRE strains. The 6 neonates with CRE sepsis were treated with sensitive antibiotics such as meropenem, amikacin and ceftazidime-avibactam, and achieved good therapeutic effects.Conclusions:Escherichia coli and Klebsiella are the main pathogens of Enterobacter sepsis in neonates, especially premature infants, with high incidence of complications and high drug resistance rate.

Craniocervical junction zone malformations often have an insidious onset, a variety of clinical phenotypes, and are often combined with multiple malformations, making their systematic classification and staging more difficult.At present, craniocervical junction area malformations are often classified into congenital and acquired, and can also be classified into skull base malformations, atlantoaxial malformations, and cardinal malformations according to their locations. For patients with obvious occipitocervical or atlantoaxial instability, combined with symptoms of high cervical spinal cord damage, internal fixation and fusion surgery should be performed aggressively to avoid irreversible nerve damage.There is a lack of detailed categorisation and summary of the treatment of diseases associated with craniocervical junction malformations in the literature, and the treatment strategies for some of these malformations are still controversial, with different perceptions and treatment concepts in the national and international literature.

Objective:To summarize and analyze the clinical characteristics, drug resistance and treatment of 36 neonates with Enterobacter sepsis in the Children′s Hospital of Soochow University in the past 3 years, so as to provide reference for clinical treatment.Methods:A retrospective analysis was conducted on neonates hospitalized in the Department of Neonatology of the Children′s Hospital of Soochow University from January 2021 to March 2024 who were diagnosed with Enterobacter sepsis. The birth status, clinical manifestations, blood culture drug sensitivity, treatment status and disease outcome of the neonates were analyzed.Results:A total of 36 neonates with Enterobacter sepsis were collected. Premature infants accounted for 38.9%(14/36), and late-onset cases accounted for 66.7%(24/36). The incidence of complications was high. The main complications were central nervous system infection (15/36, 41.7%), urinary system infection (13/36, 36.1%) and neonatal necrotizing enterocolitis (7/36, 19.4%). The main pathogenic bacteria were Escherichia coli (19 cases) and Klebsiella (11 cases). Among the 19 escherichia coli strains, 7 were extended-spectrum β-lactamase (ESBL)-producing strains and 1 was carbapenem-resistant enterobacteriaceae (CRE) strain. Among the 11 Klebsiella strains, 9 were ESBL-producing strains and 6 were CRE strains. The 6 neonates with CRE sepsis were treated with sensitive antibiotics such as meropenem, amikacin and ceftazidime-avibactam, and achieved good therapeutic effects.Conclusions:Escherichia coli and Klebsiella are the main pathogens of Enterobacter sepsis in neonates, especially premature infants, with high incidence of complications and high drug resistance rate.

Craniocervical junction zone malformations often have an insidious onset, a variety of clinical phenotypes, and are often combined with multiple malformations, making their systematic classification and staging more difficult.At present, craniocervical junction area malformations are often classified into congenital and acquired, and can also be classified into skull base malformations, atlantoaxial malformations, and cardinal malformations according to their locations. For patients with obvious occipitocervical or atlantoaxial instability, combined with symptoms of high cervical spinal cord damage, internal fixation and fusion surgery should be performed aggressively to avoid irreversible nerve damage.There is a lack of detailed categorisation and summary of the treatment of diseases associated with craniocervical junction malformations in the literature, and the treatment strategies for some of these malformations are still controversial, with different perceptions and treatment concepts in the national and international literature.

Critical care medicine-related treatment is an interdisciplinary and multi-professional process,often leading to secondary or concomitant mental disorders in clinical practice.Currently,there is no consensus on the pharmacological treatment of related mental illnesses in China.The Chinese Society of Psychosomatic Medicine collaborated with the Critical Care Medicine expert group to form a consensus writing expert group.After a systematic review of relevant literature,summarizing published domestic and foreign literature,and extensive discussions,the consensus was developed.The consensus elaborates on the principles and processes of the standardized use of psychotropic drugs in critical care medicine,as well as the clinical indications,precautions,and specific drug selection of various psychiatric medications,providing feasible suggestions and guidance for the clinical application of psychiatric medications in the intensive care unit.

Objective:To explore the efficacy and safety of finelidone combined with valsartan in the treatment of 1-3a stage chronic kidney disease (CKD) with diabetic nephropathy (DKD) .Methods:A total of 100 cases with 1~3a stage CKD with DKD were divided into two groups by random number table method. The control group was treated by valsartan on the basis of conventional treatment, and the observation group was treated by valsartan combined with finelidone.Blood glucose [fasting blood glucose (FBG), glycated hemoglobin (HbAlc), 2h postmeal blood glucose (P2hBG) ], systolic blood pressure (SBP), renal function indicators [β2 microglobulin (β2-mg), 24h urinary protein quantity (24hUPr), blood creatinine (Scr), blood urea nitrogen (BUN) and blood potassium], inflammation indicators [C-reactive protein (CRP), high mobility group protein B1 (HMGB1) and transforming growth factor β1 (TGF-β1) ], oxidative stress markers [malondialdehyde (MDA), reactive oxygen species (ROS) and antioxidant superoxide dismutase (SOD), total antioxidant capacity (T-AOC) ] and adverse reactions was compared between two groups.Results:After treatment, the levers of FBG, HbAlc, P2hBG, SBP, β2-MG, 24hUPr, Scr, BUN, CRP, HMGB1, TGF-β1, MDA and ROS in the observation group were significantly lower than those in the control group ( P<0.05). The level of SOD and T-AOC in the observation group after treatment were (120.74±16.85) U/mL and (31.38±4.16) U/mL, respectively, significantly higher than (101.62±15.82) U/mL and (20.96±3.91) U/mL in the control group, and the differences were significant ( P<0.05). After treatment, the serum potassium level in the observation group was (4.16±0.62) mmol/L, and the incidence of adverse reactions was 8.00%, while that in the control group was (4.21±0.71) mmol/L, and the incidence of adverse reactions was 10.00%, with no significant difference between the two groups ( P>0.05) . Conclusion:Finelidone combined with valsartan can improve blood glucose and blood pressure of 1~3a stage CKD with DKD and protect renal function with good safety, which may be related to reducing oxidative inflammation and enhancing antioxidant capacity of the body.

Objective:To explore the efficacy and safety of finelidone combined with valsartan in the treatment of 1-3a stage chronic kidney disease (CKD) with diabetic nephropathy (DKD) .Methods:A total of 100 cases with 1~3a stage CKD with DKD were divided into two groups by random number table method. The control group was treated by valsartan on the basis of conventional treatment, and the observation group was treated by valsartan combined with finelidone.Blood glucose [fasting blood glucose (FBG), glycated hemoglobin (HbAlc), 2h postmeal blood glucose (P2hBG) ], systolic blood pressure (SBP), renal function indicators [β2 microglobulin (β2-mg), 24h urinary protein quantity (24hUPr), blood creatinine (Scr), blood urea nitrogen (BUN) and blood potassium], inflammation indicators [C-reactive protein (CRP), high mobility group protein B1 (HMGB1) and transforming growth factor β1 (TGF-β1) ], oxidative stress markers [malondialdehyde (MDA), reactive oxygen species (ROS) and antioxidant superoxide dismutase (SOD), total antioxidant capacity (T-AOC) ] and adverse reactions was compared between two groups.Results:After treatment, the levers of FBG, HbAlc, P2hBG, SBP, β2-MG, 24hUPr, Scr, BUN, CRP, HMGB1, TGF-β1, MDA and ROS in the observation group were significantly lower than those in the control group ( P<0.05). The level of SOD and T-AOC in the observation group after treatment were (120.74±16.85) U/mL and (31.38±4.16) U/mL, respectively, significantly higher than (101.62±15.82) U/mL and (20.96±3.91) U/mL in the control group, and the differences were significant ( P<0.05). After treatment, the serum potassium level in the observation group was (4.16±0.62) mmol/L, and the incidence of adverse reactions was 8.00%, while that in the control group was (4.21±0.71) mmol/L, and the incidence of adverse reactions was 10.00%, with no significant difference between the two groups ( P>0.05) . Conclusion:Finelidone combined with valsartan can improve blood glucose and blood pressure of 1~3a stage CKD with DKD and protect renal function with good safety, which may be related to reducing oxidative inflammation and enhancing antioxidant capacity of the body.